NAD+ Side Effects: What Happens When You Push Your Cells' Energy Currency

NAD+ (nicotinamide adenine dinucleotide) occupies an unusual position in the longevity and wellness space: it is not a peptide, strictly speaking, but it appears alongside peptides constantly in research protocols, IV therapy menus, and anti-aging stacks. Its side effect profile is distinct enough, and poorly enough communicated in the popular longevity content, to warrant its own treatment.

The core thing to understand: the route of administration completely changes the side effect experience. Oral NAD+ precursors (NMN, NR), injectable NAD+, and intravenous NAD+ are pharmacologically related but practically very different from a tolerability standpoint.

NAD+ is a coenzyme found in every living cell. It is essential to mitochondrial energy production (specifically in the electron transport chain), DNA repair via PARP enzymes, and cell signalling through sirtuins (the proteins that have become central to longevity biology research following David Sinclair's work at Harvard).

NAD+ levels decline with age. By middle age, NAD+ levels in various tissues have dropped to roughly half of peak levels. This decline correlates with reduced mitochondrial function, slower DNA repair, and the metabolic characteristics of aging. The hypothesis driving NAD+ supplementation is that restoring youthful NAD+ levels would slow or partially reverse some of these processes.

The research in animal models is compelling. Human clinical trial data, while growing, is more limited, and the field is moving faster than the controlled trial base.

High-dose intravenous NAD+ is the administration route associated with the most pronounced side effects, and the one that most people are unprepared for on their first infusion.

The infusion reaction. This is the defining experience of IV NAD+ that a significant number of wellness clinics and online guides fail to adequately warn about. During an IV NAD+ infusion, particularly at higher doses or faster infusion rates, users typically experience a distinctive constellation of sensations: chest tightness or pressure, a feeling of warmth or flushing that can become intense, nausea, lightheadedness, a sense of anxiety or an unusual internal sensation variously described as "electric," "buzzing," or a feeling of cellular activation. Some users experience muscle cramps, particularly in the legs.

These are not allergic reactions. They are pharmacological reactions to NAD+ metabolism occurring in real time. They are essentially universal at higher doses and faster infusion rates.

The way IV NAD+ clinics manage this: slower infusion rates dramatically reduce the intensity of these reactions. A typical 500mg IV NAD+ infusion given over 30-60 minutes produces intense reactions in many users. The same dose given over 3-4 hours is much better tolerated. Many experienced NAD+ users and clinicians consider 2-4 hour infusion protocols standard of care precisely for this reason.

The reaction is not dangerous for most people, but the chest tightness component (which is caused by smooth muscle activation, not cardiac events) can be alarming enough to cause significant distress and treatment discontinuation. Clinics administering NAD+ without warning patients or having protocols to slow the infusion are, frankly, not doing their job properly.

Nausea and vomiting. At high doses or fast infusion rates, nausea progresses to vomiting in some users. Slowing the infusion and having a provider present to manage the rate is the reason high-quality IV therapy is done under clinical supervision.

Fatigue after infusion. A subset of users experience post-infusion fatigue lasting hours to a day. The proposed mechanism involves a temporary ATP depletion as metabolic pathways upregulate. Most users report this resolves and is followed by improved energy in subsequent days.

Who should not receive IV NAD+: People with cardiac arrhythmias, uncontrolled hypertension, or significant cardiac disease should receive medical clearance before IV NAD+ given the cardiovascular activation effects. The chest sensations and heart rate changes during infusion are benign in healthy individuals but clinically significant in vulnerable populations.

Subcutaneous and intramuscular NAD+ injections are increasingly used as an alternative to IV infusions for maintenance dosing. The side effect profile is substantially milder than IV because the rate of systemic absorption is slower and more controlled.

Injection site pain is the primary complaint. NAD+ in its injectable form has a pH and osmolarity that can cause significant burning at the injection site, particularly with intramuscular administration. Users consistently report that this is the most uncomfortable aspect of injectable NAD+ relative to other peptide injections.

The systemic reactions described with IV (flushing, chest tightness, nausea) can occur with injections but are typically much milder and shorter-lived. Fatigue post-injection is reported in some users.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are oral precursors that the body converts to NAD+. Their side effect profiles are far milder than injectable or IV NAD+ because the conversion is gradual and the systemic NAD+ increase is slower.

Most users tolerate NMN and NR without significant issues. Reported side effects include:

Nausea at high doses (typically above 1000mg daily). Nausea is the most commonly reported oral side effect and is dose-dependent.

Flushing. Mild flushing can occur, significantly less intense than with IV administration. Some users confuse this with niacin flush (which is a known side effect of high-dose niacin and is more pronounced), but the mechanism and intensity with NMN/NR are different.

Sleep effects. A proportion of users report vivid dreams or disrupted sleep with NMN, particularly when taken in the evening. Taking oral NMN in the morning is the common recommendation.

This does not appear in mainstream NAD+ content but is discussed in functional medicine communities and some longevity researcher forums.

NAD+ metabolism involves the enzyme NNMT (nicotinamide N-methyltransferase), which methylates nicotinamide as part of the clearance pathway. Sustained high-dose NAD+ precursor supplementation may consume methyl groups (specifically SAM, or S-adenosylmethionine) more rapidly. For people with pre-existing methylation issues (certain MTHFR gene variants, low folate, high homocysteine), this theoretical methyl group consumption could potentially exacerbate deficiencies.

There is no strong clinical evidence that typical NAD+ supplementation produces clinically significant methyl group depletion in healthy individuals. But in functional medicine practice, some practitioners co-administer methylation support (methyl-B12, methylfolate) with high-dose NAD+ protocols as a precaution. This is worth knowing if you see it in protocols without explanation.

NAD+ plays a role in DNA repair, and higher NAD+ levels in cancer cells support their survival and resistance to treatment in some cancer biology research. There is a theoretical concern, discussed in oncology contexts, that high-dose NAD+ supplementation could support tumour survival or growth in someone with an active cancer.

This is an unsettled area. Some NAD+ research points in the opposite direction, with NAD+ depletion strategies being explored as potential cancer treatments. The picture is not clear enough to make strong claims in either direction.

The practical takeaway: people with a history of or active cancer should discuss NAD+ supplementation with their oncologist before use. This is a genuine area of uncertainty, not performative caution.

The clinical evidence base for NAD+ supplementation in humans, particularly for longevity outcomes, is still developing. Most of the most compelling data is in animal models. Human trials exist but are smaller and more focused than the scale of popular interest in NAD+. The clinical safety profile from these trials and from widespread clinical use is reassuring for most routes and doses. But "reassuring safety profile in short-term use" is not the same as "established long-term safety data for high-dose supplementation."

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning NAD+ supplementation in any form.